Petra Langerbeins

17PUBLICATIONS
42CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursPredictive and prognostic markersInnate immunityRespiratory diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Jun 20, 2026
Ibrutinib in early stage CLL: Genetic risk factors and treatment outcome in the GCLLSG CLL12 trial.

|Jan 13, 2026
The landscape and evolution of clonal hematopoiesis in chronic lymphocytic leukemia.

Othman Al-Sawaf, Benjamin N Locher, Friederike Christen

|Sep 08, 2025
Efficacy of MRD-triggered anti-CD20 retreatment in patients with high-risk chronic lymphocytic leukemia: a case series.

Ellinor Goergen, Sandra Robrecht, Rudy Ligtvoet

|Jan 30, 2025
MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial.

Moritz Fürstenau, Sandra Robrecht, Christof Schneider

|Nov 27, 2024
Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial.

Petra Langerbeins, Sandra Robrecht, Pascal Nieper

|Aug 30, 2024
End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia.

Florian Simon, Rudy Ligtvoet, Sandra Robrecht

Pageof 3

Frequent Collaborators

7 joint publications

Paula Cramer

7 joint publications

Michael J Hallek

6 joint publications

Moritz Fürstenau

5 joint publications

Florian Simon